- Home
- INKT vs CLPR Comparison
INKT vs CLPR Comparison
Compare INKT & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | CLPR |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 51.2M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | INKT | CLPR |
|---|---|---|
| Price | $10.45 | $3.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $42.50 | N/A |
| AVG Volume (30 Days) | 14.3K | ★ 23.6K |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 11.99% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $109,997,000.00 |
| Revenue This Year | N/A | $0.91 |
| Revenue Next Year | $44.74 | $2.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.82 |
| 52 Week Low | $8.48 | $2.69 |
| 52 Week High | $15.27 | $3.94 |
Technical Indicators
Market Signals| Indicator | INKT | CLPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 57.93 |
| Support Level | $9.05 | $3.21 |
| Resistance Level | $12.27 | $3.33 |
| Average True Range (ATR) | 0.69 | 0.10 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 51.74 | 100.00 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.